S-8 1 tmb-20220815xs8.htm S-8

As filed with the Securities and Exchange Commission on March 29, 2023

Registration No. 333-

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM S-8

REGISTRATION STATEMENT

Under

The Securities Act of 1933

AEROVATE THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

 

83-1377888

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

930 Winter Street, Suite M-500

Waltham, MA 02451

(617) 443-2400

(Address, including zip code and telephone number, including area code, of Registrant’s principal executive offices)

Aerovate Therapeutics, Inc. 2021 Stock Option and Incentive Plan

Aerovate Therapeutics, Inc. 2021 Employee Stock Purchase Plan

(Full title of the plans)

Timothy P. Noyes

Chief Executive Officer

Aerovate Therapeutics, Inc.

930 Winter Street, Suite M-500

Waltham, MA 02451

(617) 443-2400

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copies to:

Edwin M. O’Connor, Esq.

Alicia M. Tschirhart, Esq.

Goodwin Procter LLP

100 Northern Avenue

Boston, Massachusetts 02210

(617) 570-1000

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

Accelerated filer

 

Non-accelerated filer

Smaller reporting company

 

 

 

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.


EXPLANATORY NOTE

Pursuant to General Instruction E of Form S-8, Aerovate Therapeutics, Inc. (the “Registrant”) is filing this registration statement with the Commission to register (1) 988,918 additional shares of the Registrant’s common stock, $0.0001 par value per share (“Common Stock”) available for issuance under the Registrant’s 2021 Stock Option and Grant Plan (the “Plan”), pursuant to the evergreen provisions of the Plan, and (2) 247,229 additional shares of Common Stock available for issuance under the Registrant’s 2021 Employee Stock Purchase Plan (the “ESPP”), pursuant to the evergreen provisions of the ESPP. This Registration Statement incorporates by reference the contents of the Registrant’s Registration Statements on Form S-8 (SEC File No. 333-257579 and SEC File No. 333- 263990), filed with the Securities and Exchange Commission on June 30, 2021 (with respect to the Plan and ESPP) and March 30, 2022 (with respect to the Plan), respectively, pursuant to General Instruction E, except for “Item 8. Exhibits.”

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 8.

Exhibits.

The exhibits to this Registration Statement are listed in the Exhibit Index attached hereto and incorporated by reference herein.


EXHIBIT INDEX

Exhibit
No.

   

Description

4.1

 

Second Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-40544) filed on July 2, 2021).

4.2

 

Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Registrant’s Registration Current Report on Form 8-K (File No. 001-40544) filed on July 2, 2021).

4.3

 

Investors’ Rights Agreement among the Registrant and certain of its stockholders, dated August 5, 2020 (incorporated by reference to Exhibit 4.2 to the Registrant’s Registration Statement on Form S-1 (File No. 333-256949) filed on June 9, 2021).

 

 

 

4.4

 

Form of Specimen Stock Certificate (incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1/A (File No. 333-256949) filed on June 17, 2021).

 

 

5.1*

 

Opinion of Goodwin Procter LLP.

 

 

23.1*

 

Consent of KPMG LLP, independent registered public accounting firm.

 

 

23.2*

 

Consent of Goodwin Procter LLP (included in Exhibit 5.1).

 

 

24.1*

 

Power of Attorney (included on signature page).

 

 

99.1

 

2021 Stock Option and Incentive Plan and forms of award agreements thereunder (incorporated by reference to Exhibit 10.2 to the Registrant’s Registration Statement on Form S-1/A (File No. 333-256949) filed on June 17, 2021).

 

 

 

99.2

2021 Employee Stock Purchase Plan (Incorporated by reference to Exhibit 10.3 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-256949)).

107*

 

Filing Fee Table

*

Filed herewith.

 


SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Waltham, Commonwealth of Massachusetts, on this 29 day of March, 2023.

 

 

AEROVATE THERAPEUTICS, INC.

 

 

 

By:

/s/ Timothy P. Noyes 

 

Name:

Timothy P. Noyes

 

Title:

Chief Executive Officer and Director

 

POWER OF ATTORNEY AND SIGNATURES

 

KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of Timothy P. Noyes and George A. Eldridge as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following person in the capacities and on the date indicated.

NAME

 

TITLE

 

DATE

 

 

 

 

 

/s/ Timothy P. Noyes

 

Chief Executive Officer and Director

 

March 29, 2023

Timothy P. Noyes

 

Principal Executive Officer

 

 

 

 

 

 

 

/s/ George A. Eldridge

 

Chief Financial Officer

 

March 29, 2023

George A. Eldridge

 

Principal Financial Officer and Principal Accounting Officer

 

 

 

 

 

 

 

/s/ Allison Dorval

 

Director

 

March 29, 2023

Allison Dorval

 

 

 

 

 

 

 

 

 

/s/ David Grayzel, M.D.

 

Director

 

March 29, 2023

David Grayzel, M.D.

 

 

 

 

 

 

 

 

 

/s/ Mark Iwicki

 

Director

 

March 29, 2023

Mark Iwicki

 

 

 

 

 

 

 

 

 

/s/ Maha Katabi, Ph.D.

 

Director

 

March 29, 2023

Maha Katabi, Ph.D.

 

 

 

 

 

 

 

 

 

/s/ Joshua Resnick, M.D.

 

Director

 

March 29, 2023

Joshua Resnick, M.D.

 

 

 

 

 

 

 

 

 

/s/ Donald J. Santel

 

Director

 

March 29, 2023

Donald J. Santel